BioCryst expects its guidance of $625 to $645 million for this year to finish at the upper end of that range. Pivotal data covering both 12-month and 6-month results are due to read out in Q3 next year. An update on the Netherton syndrome product is expected within the next few weeks, by the end of this year.
BCRX · Biocryst Pharmaceuticals Inc
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
BioCryst raised 2026 total revenue guidance to $715 to $730 million and tightened operating expense guidance to $415 to $425 million; non-GAAP operating profit was $86 million, up 70% year-over-year.
Biocryst Pharmaceuticals Inc reported a $86.7 million increase in total revenue for the nine months ended September 30, 2026, but a $605.5 million net loss driven by a $697.8 million non-cash navenibart charge related to the Astria merger.
BioCryst Pharmaceuticals raised full-year 2026 total revenue guidance to $715 million to $730 million, maintained ORLADEYO revenue guidance of $625 million to $645 million, and received FDA approval for ORLADEYO 150 mg oral pellets for patients aged 12 and older.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 4, 2026TL;DR. BioCryst reported strong revenue growth, substantially higher profitability and positive cash flow, raised total-revenue guidance, lowered operating-expense guidance and expanded ORLADEYO access. Pipeline readouts remain on track, while risks include a nonrecurring inventory contribution, pharmacy-transition complexity, competition and clinical or regulatory uncertainty.
- + BioCryst generated positive cash flow in Q3 and held $376.4 million of cash, cash equivalents, restricted cash and investments.
- − ORLADEYO revenue received a one-time benefit in the upper teens of millions of dollars from the CareMed inventory build that is not expected to recur each quarter.
- − The CareMed transition created temporary operational complexity while systems and processes were implemented.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Non-GAAP operating profit non-GAAP | $113.2M | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BCRX
this stock
Biocryst Pharmaceuticals Inc
|
$1.88B | -6.2% | -4.4% | — | 10.7% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$68.40B | +37.3% | — | — | 0.1% |
|
GALDY
Galderma Group AG
|
$51.90B | +7.4% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$44.97B | +23.5% | +4.3% | 87.6 | 2.4% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
|
$40.66B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 18, 2026
- This year
- 22
BioCryst expects its guidance of $625 to $645 million for this year to finish at the upper end of that range. Pivotal data covering both 12-month and 6-month results are due to read out in Q3 next year. An update on the Netherton syndrome product is expected within the next few weeks, by the end of this year.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BCRX | -4.7% | -5.9% | -14.6% | -13.6% | -6.2% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | +0.8% | +0.4% | -9.0% | -8.3% | -11.1% |